3DPRG at The University of Nottingham has unveiled its new lab
16 June 2015 | By Victoria White
The Additive Manufacturing and 3D Printing Research Group (3DPRG) at The University of Nottingham has unveiled its new lab.
List view / Grid view
News
Genzyme initiates Phase 1/2 clinical trial to evaluate olipudase alfa in paediatric patients
16 June 2015 | By Victoria White
The first paediatric patient has begun treatment in Genzyme’s Phase 1/2 clinical trial focused on evaluating the investigational therapy olipudase alfa...
FDA accepts Teva’s Biological License Application for reslizumab for review
15 June 2015 | By
The US Food and Drug Administration (FDA) has accepted for review Teva’s Biologics License Application (BLA) for reslizumab...
Reducing risk from bacterial endospores in aseptic preparation supported by Cherwell
15 June 2015 | By Cherwell Laboratories
Cherwell aids additional training opportunities for cleanroom biodecontamination...
CPhI Worldwide announces the opening of the annual CPhI Pharma Awards for 2015
15 June 2015 | By Victoria White
CPhI has announced the opening of the annual CPhI Pharma Awards for 2015 – with five new categories covering the entire pharmaceutical supply chain...
Tosedostat in combination with low dose cytarabine achieves primary endpoint in Phase 2 study
15 June 2015 | By Victoria White
CTI BioPharma has announced findings from a Phase 2 trial of tosedostat in combination with low dose cytarabine in patients with acute myeloid leukaemia...
Results from analyses of REVLIMID MCL-002 (SPRINT) study presented at EHA 2015
15 June 2015 | By Victoria White
Analyses of Celgene’s MCL-002 study, comparing Revlimid with investigators' choice in MCL, were presented at the European Haematology Association congress...
How a TV programme changed patients’ use of statins
15 June 2015 | By Victoria White
More than 60,000 Australians are estimated to have reduced or discontinued their use of prescribed statins following the airing of a TV programme...
NTCELL Phase I/IIa study meets endpoints
15 June 2015 | By Victoria White
A Phase I/IIa study of NTCELL, an regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease, has met its endpoints...
AstraZeneca announces Phase III results for lesinurad in combination with febuxostat in patients with tophaceous gout
15 June 2015 | By Victoria White
AstraZeneca presented results from its Phase III trial investigating lesinurad in combination with febuxostat in patients with tophaceous gout at EULAR 2015...
Positive results from Phase 3 study evaluating Cimzia in DMARD-naïve rheumatoid arthritis patients
15 June 2015 | By Victoria White
UCB has announced data from a Phase 3 study that showed the substantial benefits, at 52 weeks, of adding Cimzia to optimised methotrexate treatment...
Chickenpox vaccine can be effective and safe even in children with paediatric rheumatic disease
12 June 2015 | By Victoria White
Results from a new study show that the chickenpox vaccine can be safe even in children with rheumatic disease receiving immunosuppression treatment...
Updated results from Celgene’s FIRST Study of REVLIMID presented at European Haematology Association congress
12 June 2015 | By
Celgene International has announced updated results of its pivotal Phase III FIRST trial of REVLIMID at the European Haematology Association annual congress...
Arzerra improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukaemia
12 June 2015 | By Victoria White
Novartis has presented promising data from the Phase III COMPLEMENT 2 study of Arzerra in patients with replapsed chronic lymphocytic leukaemia...
Novartis’ Xolair improves quality of life by 78% for chronic spontaneous urticaria patients
12 June 2015 | By Victoria White
New analyses from pivotal Phase III studies show Xolair helps patients with Chronic Spontaneous Urticaria achieve improvements in quality of life measures...
